APOE and Alzheimer disease: These changes were irrespective of APOE carrier status for all SCFAs except propionate (Supplemental Table 1), where the effect of clinical diagnosis emerged when adjusting the model for APOE carrier status and where CI-AD showed increased propionate levels compared with CI-NAD (p = 0.049, Supplemental Figure 1).